X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/03/31/2854886/0/en/CORRECTION-AEON-Biopharma-Announces-Redemption-of-Public-Warrants.html
https://www.globenewswire.com/news-release/2024/03/29/2854837/0/en/AEON-Biopharma-Announces-Redemption-of-Public-Warrants.html
https://www.globenewswire.com/news-release/2024/03/29/2854830/0/en/AEON-Biopharma-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results.html
https://www.globenewswire.com/news-release/2024/03/19/2848990/0/en/AEON-Biopharma-Announces-Clinical-Update-and-Productive-End-of-Phase-2-Meeting-with-FDA-on-ABP-450-prabotulinumtoxinA-for-the-Preventive-Treatment-of-Migraine.html
https://www.globenewswire.com/news-release/2024/03/19/2848987/0/en/AEON-Biopharma-Announces-15-Million-Financing-Transaction-and-Termination-of-Forward-Purchase-Agreements.html
https://www.globenewswire.com//news-release/2024/01/18/2811952/0/en/AEON-Biopharma-Presents-Positive-Clinical-and-Pre-clinical-Data-for-ABP-450-prabotulinumtoxinA-in-Treating-Cervical-Dystonia-and-PTSD-Respectively-at-a-Leading-Neurotoxin-Conferenc.html
https://www.globenewswire.com//news-release/2023/12/12/2794700/0/en/AEON-Biopharma-Completes-Enrollment-in-Phase-2-Study-of-ABP-450-prabotulinumtoxinA-for-Preventive-Treatment-of-Chronic-Migraine.html
https://www.globenewswire.com//news-release/2023/11/13/2779046/0/en/AEON-Biopharma-Reports-Third-Quarter-2023-Financial-Results.html
https://www.globenewswire.com//news-release/2023/10/19/2763684/0/en/AEON-Biopharma-Announces-Topline-Results-from-Phase-2-Trial-of-ABP-450-prabotulinumtoxinA-for-the-Preventive-Treatment-of-Episodic-Migraine.html
https://www.globenewswire.com//news-release/2023/08/29/2733326/0/en/AEON-Biopharma-Presents-Positive-Results-from-Phase-2-Clinical-Trial-of-ABP-450-prabotulinumtoxinA-in-Cervical-Dystonia-at-the-International-Parkinson-and-Movement-Disorders-Societ.html
Market Place
Share 
